WO2003053933A1 - Dérivés d'aminocyclohexane substitué hétéroaryle - Google Patents

Dérivés d'aminocyclohexane substitué hétéroaryle Download PDF

Info

Publication number
WO2003053933A1
WO2003053933A1 PCT/EP2002/014037 EP0214037W WO03053933A1 WO 2003053933 A1 WO2003053933 A1 WO 2003053933A1 EP 0214037 W EP0214037 W EP 0214037W WO 03053933 A1 WO03053933 A1 WO 03053933A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
trans
cyclohexyl
pyrimidin
prop
Prior art date
Application number
PCT/EP2002/014037
Other languages
English (en)
Inventor
Jean Ackermann
Johannes Aebi
Henrietta Dehmlow
Hans-Peter Maerki
Olivier Morand
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Priority to BR0215257-6A priority Critical patent/BR0215257A/pt
Priority to KR10-2004-7009921A priority patent/KR20040075905A/ko
Priority to DE60216319T priority patent/DE60216319T2/de
Priority to EP02790481A priority patent/EP1458683B1/fr
Priority to MXPA04005907A priority patent/MXPA04005907A/es
Priority to CA2469380A priority patent/CA2469380C/fr
Priority to JP2003554649A priority patent/JP4316384B2/ja
Priority to AU2002366732A priority patent/AU2002366732B2/en
Publication of WO2003053933A1 publication Critical patent/WO2003053933A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention is concerned with novel cyclohexane derivatives, their manufacture and their use as medicaments.
  • the invention relates to compounds of the formula (I)
  • U is O or a lone pair
  • n and n independently from each other are 0 to 7 and m+n is 0 to 7, with the proviso that m is not 0 if V is O or S,
  • o 0 to 2
  • A is hydrogen, lower-alkyl, hydroxy-lower-alkyl, or lower-alkenyl
  • a 2 is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted by R , or
  • a 1 and A 2 are bonded to each other to form a ring and -A ⁇ A 2 - is lower-alkylene or lower-alkenylene, optionally substituted by R 1 , in which one -CH 2 - group of
  • -A ⁇ A 2 - can optionally be replaced by NR 2 , S, or O,
  • a 3 and A 4 independently from each other are hydrogen or lower-alkyl, or
  • a " and A 4 are bonded to each other to form a ring together with the carbon atom to which they are attached and -A 3 -A 4 - is -(CH 2 )2-5- >
  • A is hydrogen, lower-alkyl, or lower-alkenyl
  • a 6 is pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, optionally substituted with
  • substituents independently selected from the group consisting of lower- alkyl, lower-alkyl-cycloalkyl. thio-lower-alkoxy, cycloalkyl, carbamoyl, carboxy, carboxy-lower- alkyl, cyano, amino, mono- and dialkylamino, lower- alkoxy, lower- alkoxy-lower- alkyl, lower-alkoxy-carbonyl, lower-alkoxy- carbonyl-lower-alkyl, lower-alkenyl, lower-alkynyl, aryl, aryl-lower-alkyl, aryloxy, halogen, heteroaryl, heterocyclyl, heterocyclyl-lower-alkyl and trifluoromethyl,
  • R 1 is hydroxy, hydroxy-lower- alkyl, lower-alkoxy, lower-alkoxycarbonyl, halogen,
  • R , R , and R independently from each other are hydrogen or lower-alkyl, and pharmaceutically acceptable salts thereof, with the proviso, that the compound of formula (I) is not trans-[4-(2-Dipropylamino-ethyl)-cyclohexyl]-pyrimidin-2-yl-amine.
  • the compounds of the present invention inhibit 2,3-oxidosqualene-lanosterol cyclase (EC 5.4.99.) which is required for the biosynthesis of cholesterol, ergosterol and other sterols.
  • Causal risk factors that directly promote the development of coronary and peripheral atherosclerosis include elevated low-density lipoprotein cholesterol (LDL-C), low high- density lipoprotein cholesterol (HDL-C), hypertension, cigarette smoking and diabetes mellitus.
  • Other synergistic risk factors include elevated concentrations of triglyceride (TG)-rich lipoproteins, small, dense low-density lipoprotein particles, lipoprotein (a) (Lp(a)), and homocysteine.
  • Predisposing risk factors modify the causal or conditional risk factors and thus affect atherogenesis indirectly.
  • the predisposing risk factors are obesity, physical inactivity, family history of premature CVD, and male sex.
  • CHD coronary heart disease
  • LDL-C levels in plasma and the therapeutic advantage of lowering elevated LDL-C levels are now well established (Gotto et al., Circulation 81, 1990, 1721-1733; Stein et al., Nutr. Metab. Cardiovasc. Dis. 2, 1992, 113-156; Illingworth, Med. Clin. North. Am. 84, 2000, 23-42).
  • cholesterol lowering is greater for patients with pre- established CHD than for asymptomatic persons with hypercholesterolemia. According to current guidelines, cholesterol lowering treatment is recommended for patients who had survived a myocardial infarct or patients suffering from angina pectoris or another atherosclerotic disease, with a target LDL-C level of 100 mg/dl.
  • statins i.e. HMG-Co-A reductase inhibitors such as simvastatin and atorvastatin
  • statins i.e. HMG-Co-A reductase inhibitors such as simvastatin and atorvastatin
  • statins i.e. HMG-Co-A reductase inhibitors such as simvastatin and atorvastatin
  • statins i.e. HMG-Co-A reductase inhibitors
  • simvastatin and atorvastatin i.e. HMG-Co-A reductase inhibitors
  • atorvastatin HMG-Co-A reductase inhibitors
  • the best statins reduce plasma LDL-C effectively by at least 40%, and also plasma triglycerides, a synergistic risk factor, but less effectively.
  • fibrates reduce plasma triglycerides effectively, but not LDL-C.
  • statins are well tolerated at standard dosage, but reductions in non-sterol intermediates in the cholesterol synthesis pathway, such as isoprenoids and coenzyme Q, may be associated with adverse clinical events at high doses (Davignon et al., Can. J. Cardiol. 8, 1992, 843-864; Pederson and Tobert, Drug Safety 14, 1996, 11-24).
  • OSC 2,3-oxidosqualene:lanosterol cyclase
  • OSC inhibition does not trigger the overexpression of HMGR because of an indirect, negative feed-back regulatory mechanism involving the production of 24(S),25- epoxycholesterol (Peffley et al, Biochem. Pharmacol. 56, 1998, 439-449; Nelson et al., J.
  • the OSC inhibitors of the present invention could also indirectly activate LXR-dependent pathways such as (i) cholesterol-7alpha-hydroxylase to increase the consumption of cholesterol via the bile acid route, (ii) expression of ABC proteins with the potential to stimulate reverse cholesterol transport and increase plasma HDL-C levels (Venkateswaran et al., J. Biol. Chem. 275, 2000, 14700-14707; Costet et al., J. Biol. Chem.
  • the present compounds of formula I inhibit OSC and therefore also inhibit the biosynthesis of cholesterol, ergosterol and other sterols, and reduce the plasma cholesterol levels. They can therefore be used in the therapy and prophylaxis of hypercholesterolemia, hyperlipemia, arteriosclerosis and vascular diseases in general. Furthermore, they can be used in the therapy and/or prevention of mycoses, parasite infections, gallstones, cholestatic liver disorders, tumors and hyperproliferative disorders, e.g. hyperproliferative skin and vascular disorders. In addition, it has unexpectedly been found that the compounds of the present invention can also be of therapeutical use to improve glucose tolerance in order to treat and/or prevent related diseases such as diabetes. The compounds of the present invention further exhibit improved pharmacological properties compared to known compounds.
  • lower is used to mean a group consisting of one to seven, preferably of one to four carbon atom(s).
  • pair refers to an unbound electron pair, in particular to the unbound electron pair of a nitrogen atom in e.g. an amine.
  • halogen refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
  • alkyl refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. Lower-alkyl groups as described below also are preferred alkyl groups.
  • lower-alkyl refers to a branched or straight- chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl . t-butyl and the like.
  • cycloalkyl refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclope ⁇ tyl, or cyclohexyl.
  • alkoxy refers to the group R'-O-, wherein R' is an alkyl.
  • lower- alkoxy refers to the group R'-O-, wherein R' is a lower-alkyl.
  • thio-alkoxy refers to the group R'-S-, wherein R' is an alkyl.
  • thio-lower-alkoxy refers to the group R'-S-, wherein R' is a lower-alkyl.
  • alkenyl stands for a straight- chain or branched hydrocarbon residue comprising an olefmic bond and up to 20, preferably up to 16 carbon atoms, more preferrably up to 10 carbon atoms. Lower-alkenyl groups as described below also are preferred alkenyl groups.
  • lower-alkenyl refers to a straight- chain or branched hydrocarbon residue comprising an olefmic bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propenyl.
  • alkynyl stands for a straight- chain or branched hydrocarbon residue comprising a triple bond and up to 20, preferably up to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower-alkynyl groups as described below also are preferred alkynyl groups.
  • lower-alkynyl refers to a straight- chain or branched hydrocarbon residue comprising a triple bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propinyl.
  • alkylene refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower-alkylene groups as described below also are preferred alkylene groups.
  • lower-alkylene refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7, preferably 1 to 6 or 3 to 6 carbon atoms. Straight chain alkylene or lower-alkylene groups are preferred.
  • alkenylene refers to a straight chain or branched divalent hydrocarbon group comprising an olefmic bond and up to 20 carbon atoms, preferably up to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower-alkenylene groups as described below also are preferred alkenylene groups.
  • lower- alkenylene refers to a straight chain or branched divalent hydrocarbon group comprising an olefmic bond and up to 7, preferably up to 5, C-atoms. Straight chain alkenylene or lower-alkenylene groups are preferred.
  • aryl relates to the phenyl or naphthyl group, preferably the phenyl group, which can optionally be substituted by 1 to 3 substituents independently selected from the group consisting of lower-alkyl, lower-alkenyl, lower-alkynyl, dioxo-lower-alkylene (forming e.g.
  • a benzodioxyl group halogen, hydroxy, CN, CF 3 , NH 2) N(H, lower-alkyl), N(lower-alkyl) 2 - aminocarbonyl, carboxy, NO 2 , lower-alkoxy, thio-lower-alkoxy, lower- alkylcarbonyl, lower-alkylcarbonyloxy, lower-alkoxycarbonyl.
  • Preferred substituents are halogen, CF 3) CN, lower-alkyl and/or lower-alkoxy.
  • heteroaryl refers to an aromatic 5- or 6-membered ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as furyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, imidazolyl, or pyrrolyl.
  • a heteroaryl group may have a substitution pattern as described earlier in connection with the term "aryl”.
  • heterocyclyl denotes non-aromatic monocyclic heterocycles with 5 or 6 ring members, which comprise 1, 2 or 3 hetero atoms selected from nitrogen, oxygen and sulfur.
  • suitable heterocycles are pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, pyranyl, 4,5-dihydro-oxazolyl, 4,5-dihydro-thiazolyl.
  • a heterocyclyl group may have a substitution pattern as described earlier in connection with the term "aryl”.
  • salts embraces salts of the compounds of formula (I) with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, fumaric acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms.
  • Preferred salts are phosphates, • citrates, fumarates, formates, hydrochlorides, hydrobromides and methanesulfonic acid salts.
  • the present invention relates to compounds of formula (I)
  • U is O or a lone pair
  • n and n independently from each other are 0 to 7 and m+n is 0 to 7, with the proviso that m is not 0 if V is O or S,
  • o 0 to 2
  • a 1 is hydrogen, lower-alkyl, hydroxy-lower-alkyl, or lower-alkenyl
  • a 2 is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted by R 1 , or
  • a 1 and A 2 are bonded to each other to form a ring and -A -A - is lower-alkylene or lower-alkenylene, optionally substituted by R 1 , in which one -CH 2 - group of -A ⁇ A 2 - can optionally be replaced by NR 2 , S, or O .
  • a 3 and A 4 independently from each other are hydrogen or lower-alkyl, or
  • a 3 and A 4 are bonded to each other to form a ring together with the carbon atom to which they are attached and -A 3 -A 4 - is -(CH 2 ) 2 - 5 -,
  • a 5 is hydrogen, lower-alkyl, or lower-alkenyl
  • a 6 is pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower- alkyl, lower-alkyl-cycloalkyl, thio-lower-alkoxy, cycloalkyl, carbamoyl, carboxy, carboxy-lower-alkyl, cyano, amino, mono- and dialkylamino, lower- alkoxy, lower-alkoxy-lower-alkyl, lower-alkoxy-carbonyl, lower-alkoxy- carbonyl-lower-alkyl, lower-alkenyl, lower-alkynyl, aryl, aryl-lower-alk l, aryloxy, halogen, heteroaryl, heterocyclyl, heterocyclyl-lower-alkyl and trifluoromethyl, R 1 is hydroxy, hydroxy-lower- alkyl, lower-al
  • R 2 , R 3 , and R 4 independently from each other are hydrogen or lower-alkyl, and pharmaceutically acceptable salts thereof, with the proviso, that the compound of formula (I) is not trans- [4-(2-Dipropylamino-ethyl)-cyclohexyl]-pyrimidin-2-yl-amine.
  • Other preferred embodiments relate to compounds of formula (I) wherein U is a lone pair or to compounds of formula (I) wherein U is O.
  • m is 0 to 3, more preferably m is 0.
  • Compounds of formula (I), in which n is 0 or 1 are also preferred, with those compounds wherein n is 0 being more preferred.
  • Compounds as decsribed above, in which the number of carbon atoms of (CH 2 ) m , V and (CH ) n together is 7 or less, are also preferred.
  • Other preferred compounds of formula (I) as described above are those, wherein o is 0 or 1.
  • preferred compounds of the present invention are those in which A represents lower-alkyl, preferrably those in which A is methyl or ethyl.
  • Another group of preferred compounds of the present invention are those in which A represents lower- alkenyl, or lower-alkyl optionally substituted by R 2 , wherein R 2 is hydroxy or lower-alkoxy, with those compounds wherein A 2 represents methyl, propyl or 2-hydroxy-ethyl being especially preferred.
  • said ring is preferrably a 4-, 5-, or 6-membered ring such as e.g. piperidinyl or pyrrolidinyl.
  • a further preferred embodiment of the present invention relates to compounds of formula (I), wherein A 3 and A 4 represent hydrogen.
  • Compounds of formula (I), wherein A 5 is hydrogen or lower-alkyl also relate to a preferred embodiment of the present invention, with those compounds, wherein A is methyl relating to a particularly preferred embodiment.
  • Other preferred compounds are those in which A 6 is pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower-alkyl, lower-alkoxy, halogen, pyridyl and thienyl.
  • More preferred compounds of formula (I) are those wherein A 6 is pyridazinyl or pyrimidinyl, optionally substituted with 1 or 2 substituents independently selected from the group consisting of bromo, chloro, ethyl and pyridyl, with those compounds wherein A 6 is 5-bromo-pyrimidin-2-yl, 6-chloro- pyridazin-3-yl, 5-chloro-pyrimidin-2-yl, 5-pyridin-4-yl-pyrimidin-2-yl, 5-ethyl- pyrimidin-2-yl being particularly preferred.
  • Preferred compounds of general formula (I) are those selected from the group consisting of
  • Particularly preferred compounds of general formula (I) are those selected from the group consisting of
  • Compounds of formula (I) can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers or as racemats. They can exist as cis- or trans-isomers. The invention embraces all of these forms. Compounds of formula (I) which are trans-isomers (with reference to the cyclohexyl ring) are preferred.
  • the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • the present invention also relates to a process for the manufacture of compounds of formula (I) as described above, which process comprises
  • a 1 -A 2 ,U)N-C(A 3 ) A 4 )-(CH 2 ) m -M wherein V is O or S, M is mesylate, tosylate, triflate, CI, Br or I, and U, A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , m, n and o are as defined above, or wherein HV is mesylate, tosylate, triflate, CI, Br or I, and M is OH, SH,
  • NHA 1 A 2 wherein M is mesylate, tosylate, triflate, CI, Br or I, and A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , V, m, n and o are as defined above, and optionally converting a compound of formula (I) as defined above to a pharmaceutically acceptable salt,
  • (CH 2 ) m -M can be carried out by procedures known in the art and described in Scheme 5 in a solvent like N,N-dimethylformamide, N,N-dimethylacetamide or nitromethane in the presence of a base like sodium hydride or 2,6-di-tert-butylpyridine in a temperature range of e.g. 0°C to 80°C.
  • Reactions of a compound of formula (III) with a compound NHA 1 A 2 can be carried out by procedures known in the art and described in the examples preferentially in solvents like N-N-dimethylacetamide, N,N-dimethylformamide or methanol, preferentially between room temperature and 80°C.
  • a compound as defined above can be converted to a pharmaceutically acceptable salt by procedures known in the art such as by a treatment with a corresponding acid in a solvent like ethanol, methanol or dichloromethane in a temperature range of e.g. -20°C and +40°C.
  • a compound as defined above, wherein U is a lone pair can be converted to a compound wherein U is O by procedures known in the art such as by reaction with a mixture of hydrogen peroxide urea adduct and phthalic anhydride in dichloromethane at room temperature.
  • the invention further relates to compounds of formula (I) as defined above, when manufactured according to a process as defined above.
  • the compounds of formula (I) of the present invention can be used for the treatment and/or prophylaxis of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.
  • diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.
  • Hyperproliferative skin and vascular disorders particularly come into consideration as hyperproliferative disorders.
  • the invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
  • the invention relates to compounds as defined above for use as therapeutic active substances, particularly as therapeutic active substances for the treatment and/or prophylaxis of of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.
  • diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.
  • the invention relates to a method for the treatment and/or prophylaxis of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia, which method comprises administering a compound as defined above to a human being or animal.
  • diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia, which method comprises administering a compound as defined above to a human being or animal.
  • the invention further relates to the use of compounds as defined above for the treatment and/or prophylaxis of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.
  • diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.
  • the invention relates to the use of compounds as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.
  • diseases which are associated with OSC
  • Such medicaments comprise a compound as defined above.
  • R' protecting group
  • Compound 1 can also be first O- protected and then N-alkylated at the tert-butoxycarbonyl protected amino function with an alkyl or alkenyl halide in the presence of a base like sodium hydride in a solvent like N,N-dimethylformamide or acetonitrile at temperatures between room temperature and 80 °C to introduce substituents A 5 ; after O-deprotection the compound 3 is obtained.
  • Compound 3 is subsequently oxidized to the corresponding aldehyde 4 by using e.g. Swern conditions: oxalyl chloride/ dimethylsulfoxide/triethylamine in dichloromethane, -78 °C to room temperature (step c).
  • Cis or trans- [4- (Tert-butyl-dimethyl-silanyloxymethyl)-cyclohexyl] -methanol 1 is prepared from the corresponding bis-hydroxymethyl cyclohexane derivatives by treatment with one equivalent of n-butyl lithium in tetrahydrofuran at -78 °C followed by one equivalent of tert-butyl-dimethyl-chlorosilane at -65 °C to room temperature.
  • step c Treatment of the amino-alcohol 3 first with di-tert-butyl- dicarbonate in dichloromethane in the presence of triethylamine followed by acetic anhydride and pyridine in dichloromethane gives the di-protected compound 4 (step c).
  • Compound 4 can be N-alkylated at the primary tert-butoxycarbonyl protected amino function with an alkyl halide in the presence of a base like sodium hydride in a solvent like N,N-dimethylformamide or acetonitril at temperatures between room temperature and 80 °C to introduce substituents A 5 and give, after basic cleavage of the acetate function, the primary hydroxy compound 5 (step d).
  • the primary hydroxy compound 5 can be oxidized subsequently to the corresponding aldehyde 6 by using e.g. Swern conditions: oxalyl chloride/dimethylsulfoxide/triethylamine in dichloromethane, -78 °C to room temperature (step e).
  • a 5 substituted cyclohexanol 1 is synthesized by hydrogenation of the corresponding 4- aminophenol, 4-hydroxybenzylamine or tyramine.
  • Amine 1 is converted to the N- protected-derivative 2 (e.g. ZCl, Na 2 CO 3 /THF/H 2 O) (step a).
  • Oxidation with TEMPO (2,2,6, 6-Tetramethylpiperidine 1-oxyl, radical) and sodium hypochlorite gives ketone 3 (step b).
  • Wittig reaction with (methoxymethyl)triphenylphosphonium chloride 4 in THF and potassium t-butoxide as base gives enolether 5 (step c).
  • step d Hydrolyses of enolether 5 with 1 N HC1 in THF at reflux (step d) gives aldehyde 6.
  • the crude aldehyde 6 (as a cis/trans mixture) can be isomerised via bisulfite-adduct 7 (with disodium pyrosulfite in water/TBME, step e).
  • Bisulfite adduct 7 can then be converted to the pure trans-aldehyde 8 with aqueous Na 2 CO 3 in water/TBME (step f).
  • Compound 2 can also be first O-protected and then N-alkylated at the tert-butoxycarbonyl protected amino function with an A 5 -halide in the presence of a base like sodium hydride in a solvent like N-N-dimethylformamide or acetonitrile at temperatures between room temperature and 80 °C to introduce substituents A 5 ; after O-deprotection compound 3 is obtained (step b) and then transferred into the desired A 6 -derivative 4b (step c).
  • step c Reaction of step c maybe performed in two steps:
  • phase transfer conditions e.g. ⁇ , ⁇ -dihaloalkanes or ⁇ , ⁇ - dihaloalkenes, NaOH, nBu 4 NHSO
  • R" protected R"OCH 2 (CH 2 ) m N-Spacer can be introduced with in situ generation of the R"OCH 2 (CH 2 ) m O-triflate (from the corresponding R'O-alkanol with trifluoromethansulfonic anhydride/2,6-di-tert-butylpyridine in CH 2 C1 2 at 0 °C).
  • This triflate is then reacted with alcohol 3 with 2,6-di-tert-butylpyridine as base in nitromethane at RT to 60 °C to yield R"OCH 2 (CH 2 ) m V-elongated 3 [following a procedure of Belostotskii, Anatoly M.; Hassner, Alfred.
  • Second step Heteroaryl A 6 -introduction to give 4b can be done with different conditions: Method A: Reaction of compound 4a with 2-Halo-heteroaryl/ N- ethyldiisopropylamine lh to 5 days at 80 to 120 °C in DMA or no solvent, or Method B (for less reactive compounds): Reaction of compound 4a with 2-Halo-heteroaryl/ N- ethyldiisopropylamine/CuI or Nal for 1-10 h at 120 °C or with microwave heating for 0.5 to 6 h at 120-150 °C in DMA.
  • the starting material is cyclohexane-carboxylic acid 5 which is commercially available or van be synthesized (e.g. from aldehyde 6 by oxidation, scheme 3).
  • Acid 5 is converted to the derivative 6 by ester formation (e.g. carbonyl-di-imidazole, methanol in THF) and optionally A 5 -alkylated using sodium hydride and a reactive alkyl or alkenyl derivative (step d).
  • Reduction with lithium aluminum hydride yields the N- protected alcohol 7 which can be transformed to 4b (step f) as described for 3 to 4b.
  • the starting material is cyclohexyl acetic acid 5 (can be derived from 4- nitrophenylacetic acid according to Karpavichyus, K. I.; Palaima, A. I.; Knunyants, I. L.;
  • cyclohexyl acetic acid 5 can be synthesized (e.g. from ketone 3 scheme 3; via C 2 -elongation by Horner-Emmons reaction with triethyl phosphono acetate, sodium alcoholate) and protected as discussed before.
  • the starting material is cyclohexane-carboxylic acid 5.
  • Acid chain elongation (n>l) can be achieved using methods known in the art or as described below:
  • This aldehyde 9 can be treated with triphenylphosphine, tetrabromomethane and triethylamine in CH C1 2 at 0 °C to RT to yield 2,2-Dibromo-vinyl derivative 10.
  • substitution pattern for A 6 in product 4b can be manipulated: e.g. by Suzuki reactions if A is a Halo-heteroaryl or by nucleophilic displacements, e.g. if A is 6- Chloro-pyridazine, reaction with sodium alcoholate in DMA at 80 °C gives the alkoxy substituted compound.
  • the cyclohexanol derivative 1 (synthesis see scheme 1-4) can be treated under phase transfer conditions e.g. ⁇ , ⁇ -dihaloalkanes or ⁇ , ⁇ -dihaloalkenes, NaOH, nBu NHSO to yield bromide 2.
  • alcohol derivative 1 may be treated with ⁇ . ⁇ -dihaloalkane (for C or longer alkanes) in the presence of NaH in DMF 0 °C to RT to yield bromide 2.
  • the method of choice is the in situ generation of the haloalkane-triflate (from the corresponding haloalkanol with trifluoromethansulfonic anhydride/2,6-di-tert-butylpyridine in CH 2 C1 2 at 0 °C).
  • This haloalkane-triflate is then reacted with alcohol 1 with 2,6-di-tert-butylpyridine as base in nitromethane at RT to 60 °C to yield bromide 2 [following a procedure of Belostotskii, Anatoly M.; Hassner, Alfred. Synthetic methods. 41. Etherification of hydroxysteroids via triflates. Tetrahedron Lett. (1994), 35(28), 5075-6].
  • the second substitutent can be introduced in a second step, e.g. N- methylation with NaH 2 PO 3 /formaldehyde.
  • Amine 3 may be converted to a salt or to the N- oxide 4 using a mixture of hydrogen peroxide urea adduct and phthalic anhydride in CH 2 C1 2 at RT.
  • fragment A 1 A 2 NC(A 3 A 4 )(CH 2 ) m -OH can also be mesylated/halogenated and reacted with derivative 1 using alkylating conditions (step d).
  • the amine 5 can be converted to its salt or the N-oxide 6 as described above (step c).
  • substitution pattern for A 6 in product 5 can be manipulated: e.g. hydrolysis of a N-acetyl group to an NH 2 or by Suzuki reactions if A 6 is a Halo-heteroaryl or by nucleophilic displacements, e.g. if A is 6-Chloro-pyridazine, reaction with sodium alcoholate in DMA at 80 °C gives the alkoxy substituted compound.
  • substitution pattern of A 1 or A 2 may be modified, e.g. treatment of hydroxyethylamine with DAST.
  • dibromoalkene 2 is performed with n- BuLi (ca 1.6 M in hexane) in THF at -78 °C as above, followed by addition of a cosolvens such as DMPU and reaction with O-protected 1-bromo-alcohols 4 to yield the O- protected compounds 3a which can be deprotected to the corresponding alkynol 3a derivative in MeOH at 50-60 °C in the presence of catalytic amount of pyridinium toluene-4-sulfonate.
  • BOC-deprotection (TFA, CH 2 C1 2 ) followed by treatment with A - heteroaryl as described before (scheme 4) gives compounds of the formula 3b (step c).
  • compounds 2 can be reacted with compounds 10 under the same condition as described for step c.
  • the building blocks 10 can be prepared by known methods.
  • a two step procedure has to be followed: first the rearrangement dibromide 2 with n-BuLi (ca 1.6 M in hexane) in THF at -78 °C, followed by reaction with the corresponding aldehyde (A 3 or A 4 -COH) or ketone (A 3 COA 4 , at -78 °C to RT) leading to the A 3 ,A 4 substituted propargyl alcohol which can be transformed to a phosphorester [see: Bartlett, Paul A.; McQuaid, Loretta A..
  • substitution pattern for A 6 in product 6b or 8 can be manipulated: e.g. hydrolysis of a N-acetyl group to an NH 2 or by Suzuki reactions if A 6 is a Halo-heteroaryl or by nucleophilic displacements, e.g. if A 6 is 6-Chloro-pyridazine, reaction with sodium alcoholate in DMA at 80 °C gives the alkoxy substituted compound.
  • substitution pattern of A 1 or A 2 may be modified, e.g. treatment of hydroxyethylamine with DAST.
  • the second substitutent can be introduced in a second step, e.g. N-methylation with NaH 2 PO 3 /formaldehyde.
  • the amines 6b and 8 can be converted to a salt or as described in step f to the N- oxide 7 and 9, respectively, using a mixture of hydrogen peroxide urea adduct and phthalic anhydride in CH 2 C1 2 at RT.
  • the synthesis of the main intermediate 2 begins by attaching an ⁇ - hydroxyalkylcarbonic acid ester to alcohol 1 via the in situ generated triflate in analogy to Belostotskii, Anatoly M.; Hassner, Alfred. Synthetic methods. 41. Etherification of hydroxysteroids via triflates. Tetrahedron Lett. (1994), 35(28), 5075-6 (step a).
  • the ester 2 can be prepared from the bromide 3 (synthesis described in scheme 5) by treatment with e.g. acetocyanhydrine in acetonitrile, followed by a Pinner reaction and hydrolysis of the imidate to the corresponding ester (step b).
  • the ester 2 or its corresponding acid may be prepared from aldehyde 4 (synthesis described in scheme 1-4) by treatment with the corresponding Wittig reagent Ph 3 P(CH 2 ) m+ iCO 2 /H.
  • ester 2 or amide 6a may be derived from the dibromoderivative 5
  • dibromoalkene 5 may be performed with n-BuLi (ca 1.6 M in hexane) in THF at -78 °C as above, followed by addition of a cosolvens such as DMPU and reaction with a suitable protected 1-bromo-alkylalcohol Br-(CH2) m CH 2 OH, followed by oxidation to yield the compound 2 as acid (step e).
  • amide 6d can be treated with a grignard reagent A 3 MgX to give the corresponding ketone 8.
  • substitution pattern for A 6 in product 7 can be manipulated: e.g. hydrolysis of a N-acetyl group to an NH 2 or by Suzuki reactions if A is a Halo-heteroaryl or by nucleophilic displacements, e.g. if A 6 is 6-Chloro-pyridazine, reaction with sodium alcoholate in DMA at 80 °C gives the alkoxy substituted compound.
  • substitution pattern of A or A 2 maybe modified, e.g. treatment of hydroxyethylamine with DAST.
  • the second substitutent can be introduced in a second step, e.g. N-methylation with NaH 2 PO 3 /formaldehyde.
  • Amine 7 may be converted to a salt or to the N-oxide 9 using a mixture of hydrogen peroxide urea adduct and phthalic anhydride in CH 2 CI 2 at RT.
  • Pure cis- or trans- aminocyclohexane derivatives can be obtained either by separation of the mixtures using HPLC or by using stereochemically defined starting materials.
  • Liver microsomes from a healthy volunteer were prepared in sodium phosphate . buffer (pH 7.4).
  • the OSC activity was measured in the same buffer, which also contained ImM EDTA and ImM dithiothreitol.
  • the microsomes were diluted to 0.8mg/ml protein in cold phosphate buffer.
  • Dry [ 14 C]R,S-monooxidosqualene (MOS, 12.8 mCi/mmol) was diluted to 20 nCi/ ⁇ l with ethanol and mixed with phosphate buffer-1% BSA (bovine serum albumin).
  • BSA bovine serum albumin
  • microsomes 40 ⁇ l of microsomes were mixed with 20 ⁇ l of the solution of the test substance and the reaction was subsequently started with 20 ⁇ l of the [ 1 C]R,S-MOS solution.
  • the final conditions were: 0.4mg/ml of microsomal proteins and 30 ⁇ l of [ 14 C]R,S-MOS in phosphate buffer, pH 7.4, containing 0.5% albumin, DMSO ⁇ 0.1% and ethanol ⁇ 2%, in a total volume of 80 ⁇ l.
  • the test was carried out on the one hand with a constant test substance concentration of lOOnM and the percentage OSC inhibition against controls was calculated. The more preferred compounds of the present invention exhibit inhibitions larger than 50%.
  • the test was carried out with different test substance concentrations and subsequently the IC 50 value was calculated, i.e. the concentration required to reduce the conversion of MOS into lanosterol to 50% of the control value.
  • the preferred compounds of the present invention exhibit IC 50 values of 1 nM to 10 ⁇ M, preferrably of 1 - 100 nM.
  • the compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration.
  • They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of . ointments, creams or oils. Oral administration is preferred.
  • the production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described - compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
  • lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).
  • Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
  • Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
  • Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
  • Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
  • Usual stabilizers preservatives, wetting and emulsifying agents, consistency- improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
  • the dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 100 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
  • the pharmaceutical preparations conveniently contain about 1-500 mg, preferably
  • trans-3-(4-Methylamino-cyclohexyl)-prop-2-yn-l-ol and 2- fluoropyridine gave after 5 days at 120 °C trans-3- [4-(Methyl-pyridin-2-yl-amino)- cyclohexyl]-prop-2-yn-l-ol, MS: 245 (MH + ).
  • trans-3-(4-Methylamino-cyclohexyl)-prop-2-yn-l-ol and 2- chloropyrazine gave trans-3-[4-(Methyl-pyrazin-2-yl-amino)-cyclohexyl]-prop-2-yn-l-ol, mp: 147-149 °C, dec; MS: 246 (MH + ).
  • trans-3-(4-Methylamino-cyclohexyl)-prop-2-yn-l-ol and 3- chloro-6-methylpyridazine gave, with no Nal after 4 h at 150 °C and 3/4 h at 120 °C in the microwave oven, trans-3- ⁇ 4-[Methyl-(6-methyl-pyridazin-3-yl)-amino]-cyclohexyl]- prop-2-yn-l-ol, MS: 260 (MH + ).
  • trans-6- ⁇ [4-(3-Hydroxy-prop-l-ynyl)-cyclohexyl]-methyl- amino ⁇ -nicotinonitrile was converted to trans-Methanesulfonic acid 3- ⁇ 4-[(5-cyano- pyridin-2-yl)-methyl-amino]-cyclohexyl ⁇ -prop-2-ynyl ester, MS: 348 (MH + ).
  • trans-3- ⁇ 4-[(5-Chloro-pyrimidin-2-yl)-methyl-amino]- cyclohexyl ⁇ -prop-2-yn-l-ol was converted to trans-Methanesulfonic acid 3- ⁇ 4-[(5-chloro- pyrimidin-2-yl)-methyl-amino]-cyclohexyl ⁇ -prop-2-ynyl ester, MS: 357 (MH + , 1C1).
  • trans-3- ⁇ 4-[(5-Bromo-pyridin-2-yl)-methyl-a ⁇ nino]- cyclohexyl ⁇ -prop-2-yn-l-ol was converted to trans-Methanesulfonic acid 3- ⁇ 4-[(5-bromo- pyridin-2-yl)-methyl-amino]-cyclohexyl ⁇ -prop-2-ynyl ester, MS: 401 (MH + , IBr).
  • trans-3- [4-(Methyl-pyridin-2-yl-amino)-cyclohexyl]-prop-2- yn-l-ol was converted to trans-Methanesulfonic acid 3-[4-(methyl-pyridin-2-yl-amino)- cyclohexyl] -prop-2-ynyl ester, MS: 323 (MH + ).
  • trans-3- [4- (Methyl-pyrazin-2-yl-amino) -cyclohexyl] -prop-2- yn-l-ol was converted to trans-Methanesulfonic acid 3-[4-(methyl-pyrazin-2-yl-amino)- cyclohexyl]-prop-2-ynyl ester, MS: 324 (MH + ).
  • trans-3- ⁇ 4-[(5-Ethyl-pyrimidin-2-yl)-methyl-amino]- cyclohexyl ⁇ -prop-2-yn-l-ol was converted to trans-l-(3- ⁇ 4-[(5-Ethyl-pyrimidin-2-yl)- methyl-amino]-cyclohexyl ⁇ -prop-2-ynyl)-pyridinium; methanesulfonate, MS: 335 (MH + ).
  • trans-4- ⁇ 4-[(5-Bromo-pyrimidin-2-yl)-methyl-amino]- cyclohexyl ⁇ -but-3-yn-l-ol was converted to trans-Methanesulfonic acid 4- ⁇ 4-[(5-bromo- pyrimidin-2-yl)-methyl-amino]-cyclohexyl ⁇ -but-3-ynyl ester, MS: 416 (MH + , IBr).
  • trans-Methanesulfonic acid 4- ⁇ 4-[(5-bromo-pyrimidin-2-yl)- methyl-amino] -cyclohexyl ⁇ -but-3-ynyl ester and piperidine gave after 4.5 h at 65 °C, trans- (5-Bromo-pyrimidin-2-yl)-methyl-[4-(4-piperidin-l-yl-but-l-ynyl)-cyclohexyl ,-amine, MS: 405 (MH + , IBr).
  • trans-4- ⁇ 4-[(5-Bromo-pyrimidin-2-yl)-methyl-amino]- cyclohexyl ⁇ -butan-l-ol yielded after 2.5 h trans-Methanesulfonic acid 4- ⁇ 4-[(5-bromo- pyrimidin-2-yl)-methyl-amino]-cyclohexyl ⁇ -butyl ester, MS: 420 (MH + , IBr).
  • trans-Methanesulfonic acid 4- ⁇ 4-[(5-bromo-pyrimidin-2-yl)- methyl-amino] -cyclohexyl ⁇ -butyl ester and piperidine gave after 7 h at 65 °C, trans-(5- Bromo-pyrimidin-2-yl)-methyl-[4-(4-piperidin-l-yl-butyl)-cyclohexyl] -amine, MS: 409 (MH + , IBr).
  • trans-4-(4-Methylamino-cyclohexyl)-but-2-yn-l-ol and 3,6- dichloropyridazine gave, with no Nal after 6 h at 80 °C and 3/4 h at 120 °C in the microwave oven, trans-4- ⁇ 4-[(6-Chloro-pyridazin-3-yl)-methyl-amino]-cyclohexyl ⁇ -but- 2-yn-l-ol, MS: 294 (MH + , 1C1).
  • trans-4- ⁇ 4-[(5-Bromo-pyrimidin-2-yl)-methyl-amino]- cyclohexyl ⁇ -but-2-yn-l-ol was converted to trans-methanesulfonic acid 4- ⁇ 4-[(5-bromo- pyrimidin-2-yl)-methyl-amino]-cyclohexyl ⁇ -but-2-ynyl ester, MS: 416 (MH + , IBr).
  • trans- [4- (2-amino-ethyl)-cyclohexyl] -methanol HCl-salt with 5.4 eq N-ethyldiisopropylamine and 1.2 eq 2,5-dibromo-pyrimidine in DMA for 7.5 h at 85 °C gave trans- ⁇ 4-[2-(5-Bromo-pyrimidin-2-ylamino)-ethyl]-cyclohexyl ⁇ -methanol, mp: 151.7-153.4 °C; MS: 314 (MH + , IBr).
  • trans-(5-Bromo-pyrimidin-2-yl)-[4-(3-dimethylamino-prop- 1 -ynyl) -cyclohexyl] -methyl-amine and thiophene-3-boronic acid was converted to trans- [4-(3-Dimethylamino-prop-l-ynyl)-cyclohexyl]-methyl-(5-thiophen-3-yl-pyrimidin-2- yl)-amine, MS: 355 (MH + ).
  • trans-3-(4- ⁇ [(5-Bromo-pyrimidin-2-yl)-methyl-amino]- methyl ⁇ -cyclohexyl)-prop-2-yn-l-ol gave trans-Methanesulfonic acid 3-(4- ⁇ [(5-bromo- pyrimidin-2-yl)-methyl-amino]-methyl ⁇ -cyclohexyl)-prop-2-ynyl ester, MS: 416 (MH + , IBr).
  • trans-3-(4-Methylaminomethyl-cyclohexyl)-prop-2-yn-l-ol with 5 eq N- ethyldiisopropylamine and 4 eq 2-chloro-5-ethylpyrimidine gave, with no Nal after 3.75 h at 120 °C in the microwave oven, trans-3-(4- ⁇ [(5-Ethyl-pyrimidin-2-yl)- methyl-amino]-methyl ⁇ -cyclohexyl)-prop-2-yn-l-ol, mp: 69-71 °C; MS: 228 (MH+).
  • trans-3-(4- ⁇ [(5-Ethyl-pyrimidin-2-yl)-methyl-amino]- methyl ⁇ -cyclohexyl)-prop-2-yn-l-ol gave trans-Methanesulfonic acid 3-(4- ⁇ [(5-ethyl- pyrimidin-2-yl)-methyl-amino]-methyl ⁇ -cyclohexyl)-prop-2-ynyl ester, MS: 366 (MH + ).
  • trans-3-(4-Methylaminomethyl-cyclohexyl)-prop-2-yn-l-ol with 3.4 eq N- ethyldiisopropylamine and 4 eq 3,6-dichloropyridazine gave, with no Nal after 30 min at 120-140 °C in the microwave oven, trans-3-(4- ⁇ [(6-Chloro-pyridazin-3- yl)-methyl-amino]-methyl ⁇ -cyclohexyl)-prop-2-yn-l-ol, MS: 294 (MH+, 1C1).
  • trans-3-(4- ⁇ [(6-Chloro-pyridazin-3-yl)-methyl-amino]- methyl ⁇ -cyclohexyl) -prop-2-yn-l-ol gave trans-Methanesulfonic acid 3-(4- ⁇ [(6-chloro- pyridazin-3-yl)-methyl-amino]-methyl ⁇ -cyclohexyl)-prop-2-ynyl ester, MS: 372 (MH + , 1C1).
  • trans-4-Methylamino-cyclohexanol and 2,5-dibromo- pyrimidine was converted to trans-4-[(5-Bromo-pyrimidin-2-yl)-methyl-amino]- cyclohexanol, mp: 140-142 °C; MS: 286 (MH + , IBr).
  • trans-Methanesulfonic acid 4- ⁇ 2-[(5-bromo-pyrimidin-2-yl)- methyl-amino]-ethyl ⁇ -cyclohexylmethyl ester and 3-amino-l-propanol with 1 eq of Nal in DMA at 60 °C for 46 h gave trans-3-[(4- ⁇ 2-[(5-Bromo-pyrimidin-2-yl)-methyl-amino]- ethyl ⁇ -cyclohexylmethyl)-amino]-propan-l-ol, MS: 385 (MH+, IBr).
  • trans-3-(4-Methylaminomethyl-cyclohexyl)-prop-2-yn-l-ol with 5.4 eq N-ethyldiisopropylamine and 1.2 eq 2-chloro-5-n-propylpyrimidine gave, with no Nal after 4 h at 120 °C in the microwave oven, trans-3-(4- ⁇ [Methyl-(5-propyl- pyrimidin-2-yl)-amino]-methyl ⁇ -cyclohexyl)-prop-2-yn-l-ol, mp: 78-79 °C; MS: 302
  • trans-3-(4- ⁇ [Methyl-(5-propyl-pyrimidin-2-yl)-amino]- methyl ⁇ -cyclohexyl)-prop-2-yn-l-ol gave trans-Methanesulfonic acid 3-(4- ⁇ [methyl-(5- propyl-pyrimidin-2-yl)-amino]-methyl ⁇ -cyclohexyl)-prop-2-ynyl ester, MS: 380 (MH + ).
  • trans-3-(4- ⁇ [(5-Chloro-pyrimidin-2-yl)-methyl-ammo]- methyl ⁇ -cyclohexyl)-prop-2-yn-l-ol gave trans-Methanesulfonic acid 3-(4- ⁇ [(5-chloro- pyrimidin-2-yl)-methyl-amino]-methyl ⁇ -cyclohexyl)-prop-2-ynyl ester, MS: 372 (MH+, 1C1).
  • trans-Methanesulfonic acid 3-(4- ⁇ [methyl-(5-propyl-pyrimidin- 2-yl)-amino]-methyl ⁇ -cyclohexyl)-prop-2-ynyl ester and Dimethylamine (33% in EtOH 5.6M) in DMA gave trans-[4-(3-Dimethylamino-prop-l-ynyl)-cyclohexylmethyl]-methyl-
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water.
  • the granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
  • the kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner:
  • the components are sieved and mixed and filled into capsules of size 2.
  • Injection solutions can have the following composition:
  • Water for injection solutions ad 1.0 ml
  • the active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by Acetic Acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • Sachets containing the following ingredients can be manufactured in a conventional manner:
  • Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
  • Flavoring additives 1.0 mg
  • the active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water.
  • the granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

la présente invention concerne des composés représentés par la formule (I) dans laquelle A?1, A2, A3, A4, A5, A6¿, U, V, m, n et o sont conformes aux définitions qui en sont données dans le descriptif et les revendications, ainsi que des sels acceptables au plan pharmaceutique de ces dérivés. Ces dérivés conviennent pour le traitement et la prophylaxie de maladies associées à la 2,3-oxydosqualènelanostérol cyclase telles que l'hypercholestérolémie, l'hyperlipémie, l'artériosclérose, les maladies vasculaires, les mycoses, les infections parasitaires, les calculs biliaires, les tumeurs et/ou les troubles hyperprolifératifs ainsi que pour le traitement et/ou la prophylaxie de la diminution de tolérance au glucose et du diabète.
PCT/EP2002/014037 2001-12-20 2002-12-11 Dérivés d'aminocyclohexane substitué hétéroaryle WO2003053933A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR0215257-6A BR0215257A (pt) 2001-12-20 2002-12-11 Compostos, processos para a manufatura de compostos, composições farmacêuticas, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com "osc" e utilização dos compostos
KR10-2004-7009921A KR20040075905A (ko) 2001-12-20 2002-12-11 헤테로아릴 치환된 아미노사이클로헥세인 유도체
DE60216319T DE60216319T2 (de) 2001-12-20 2002-12-11 Heteroaryl-substituierte aminocyclohexan-derivate
EP02790481A EP1458683B1 (fr) 2001-12-20 2002-12-11 Derives d'aminocyclohexane substitut heteroaryle
MXPA04005907A MXPA04005907A (es) 2001-12-20 2002-12-11 Derivados de aminociclohexano heteroarilsustituidos.
CA2469380A CA2469380C (fr) 2001-12-20 2002-12-11 Derives d'aminocyclohexane substitue heteroaryle
JP2003554649A JP4316384B2 (ja) 2001-12-20 2002-12-11 ヘテロアリール置換アミノシクロヘキサン誘導体
AU2002366732A AU2002366732B2 (en) 2001-12-20 2002-12-11 Heteroaryl-substituted aminocyclohexane derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01130284.1 2001-12-20
EP01130284 2001-12-20

Publications (1)

Publication Number Publication Date
WO2003053933A1 true WO2003053933A1 (fr) 2003-07-03

Family

ID=8179606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/014037 WO2003053933A1 (fr) 2001-12-20 2002-12-11 Dérivés d'aminocyclohexane substitué hétéroaryle

Country Status (16)

Country Link
US (1) US7012077B2 (fr)
EP (1) EP1458683B1 (fr)
JP (1) JP4316384B2 (fr)
KR (1) KR20040075905A (fr)
CN (1) CN1296357C (fr)
AR (1) AR038549A1 (fr)
AT (1) ATE346045T1 (fr)
AU (1) AU2002366732B2 (fr)
BR (1) BR0215257A (fr)
CA (1) CA2469380C (fr)
DE (1) DE60216319T2 (fr)
ES (1) ES2275939T3 (fr)
MX (1) MXPA04005907A (fr)
PL (1) PL370713A1 (fr)
RU (1) RU2286987C2 (fr)
WO (1) WO2003053933A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1464335A2 (fr) * 2003-03-31 2004-10-06 Taisho Pharmaceutical Co. Ltd. Derives de quinolines, tetrahydroquinolines et pyrimidines comme antagonistes du mch
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225393C1 (ru) * 2000-08-16 2004-03-10 Ф.Хоффманн-Ля Рош Аг Новые производные аминоциклогексана
ZA200507112B (en) * 2003-03-31 2007-03-28 Taisho Pharmaceutical Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
CA2545048A1 (fr) * 2003-11-20 2005-06-02 Warner-Lambert Company Llc Modulateurs du recepteur androgene
ITMI20110666A1 (it) * 2011-04-19 2012-10-20 Dipharma Francis Srl Procedimento per la preparazione di (r) ed (s) pramipexolo e suoi intermedi

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0636367A1 (fr) * 1993-07-14 1995-02-01 F. Hoffmann-La Roche Ag Utilisation des phénylalkylamines pour la préparation des agents pour abaisser le taux de cholestérol
EP0778264A1 (fr) * 1995-12-08 1997-06-11 F. Hoffmann-La Roche Ag Amines tertiaires ayant une activité antimycotique et hypocholestérolémique
WO2002020483A1 (fr) * 2000-09-08 2002-03-14 F. Hoffmann-La Roche Ag Nouveaux dérivés de pipéridine
WO2002036584A1 (fr) * 2000-11-02 2002-05-10 F. Hoffmann-La Roche Ag Benzo[b]thiophenes et denzo[d]isothiazoles hypocholesterolemiants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO122123B (fr) 1966-03-25 1971-05-24 Miles Lab
US3592824A (en) 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
DE4239151A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0636367A1 (fr) * 1993-07-14 1995-02-01 F. Hoffmann-La Roche Ag Utilisation des phénylalkylamines pour la préparation des agents pour abaisser le taux de cholestérol
EP0778264A1 (fr) * 1995-12-08 1997-06-11 F. Hoffmann-La Roche Ag Amines tertiaires ayant une activité antimycotique et hypocholestérolémique
WO2002020483A1 (fr) * 2000-09-08 2002-03-14 F. Hoffmann-La Roche Ag Nouveaux dérivés de pipéridine
WO2002036584A1 (fr) * 2000-11-02 2002-05-10 F. Hoffmann-La Roche Ag Benzo[b]thiophenes et denzo[d]isothiazoles hypocholesterolemiants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WERMUTH ET AL: "The Practise of Medicinal Chemistry", PRACTICE OF MEDICINAL CHEMISTRY, XX, XX, 1996, pages 203 - 237, XP002190259 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1464335A2 (fr) * 2003-03-31 2004-10-06 Taisho Pharmaceutical Co. Ltd. Derives de quinolines, tetrahydroquinolines et pyrimidines comme antagonistes du mch
WO2004087669A1 (fr) * 2003-03-31 2004-10-14 Taisho Pharmaceutical Co. Ltd. Nouveaux derives quinoline, tetrahydroquinazoline et pyrimidine, procedes de traitement en liaison avec l'utilisation de ces derniers
EP1464335A3 (fr) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Derivés de quinolines, tetrahydroquinolines et pyrimidines comme antagonistes du MCH
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
US9657008B2 (en) 2013-01-23 2017-05-23 Astrazeneca Ab Chemical compounds
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US10351553B2 (en) 2017-01-23 2019-07-16 Cadent Therapeutics, Inc. Potassium channel modulators
US10717728B2 (en) 2017-01-23 2020-07-21 Cadent Therapeutics, Inc. Potassium channel modulators
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators

Also Published As

Publication number Publication date
KR20040075905A (ko) 2004-08-30
US20030186984A1 (en) 2003-10-02
CA2469380A1 (fr) 2003-07-03
CA2469380C (fr) 2010-01-26
RU2286987C2 (ru) 2006-11-10
AU2002366732B2 (en) 2006-11-02
EP1458683B1 (fr) 2006-11-22
CN1296357C (zh) 2007-01-24
BR0215257A (pt) 2004-12-07
US7012077B2 (en) 2006-03-14
JP2005517667A (ja) 2005-06-16
RU2004122480A (ru) 2005-08-10
DE60216319T2 (de) 2007-05-31
DE60216319D1 (en) 2007-01-04
JP4316384B2 (ja) 2009-08-19
AR038549A1 (es) 2005-01-19
PL370713A1 (en) 2005-05-30
MXPA04005907A (es) 2004-09-13
ATE346045T1 (de) 2006-12-15
ES2275939T3 (es) 2007-06-16
AU2002366732A1 (en) 2003-07-09
CN1610669A (zh) 2005-04-27
EP1458683A1 (fr) 2004-09-22

Similar Documents

Publication Publication Date Title
US5872115A (en) 2-ureido-benzamide derivatives
US7442791B2 (en) Aminoalkylamide substituted cyclohexyl derivatives
EP1458683B1 (fr) Derives d'aminocyclohexane substitut heteroaryle
JP2002539112A (ja) ニューロキニン−１受容体の拮抗薬としてのビフェニル誘導体
US6965048B2 (en) Hydroxyalkylamide derivatives
JP4339913B2 (ja) ヒドロキシアルキルアミド類
AU2002358096B2 (en) Substituted cyclohexane derivatives
JPH07242647A (ja) チアゾリン誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2469380

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002790481

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005907

Country of ref document: MX

Ref document number: 2002366732

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20028256654

Country of ref document: CN

Ref document number: 2003554649

Country of ref document: JP

Ref document number: 1020047009921

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004122480

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2002790481

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002790481

Country of ref document: EP